Status:
COMPLETED
A Study of BMS-562086 in Patients With Irritable Bowel Syndrome
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Irritable Bowel Syndrome
Eligibility:
FEMALE
18-65 years
Phase:
PHASE2
Brief Summary
The primary purpose of this study is to evaluate the effects of BMS-562086 on small bowel and colonic transits in female subjects with diarrhea-predominant irritable bowel syndrome (D-IBS)
Eligibility Criteria
Inclusion
- Female subjects with D-IBS symptoms based on Rome II criteria and the subject's responses to the Bowel Disease Questionnaire
Exclusion
- Clinically significant prolonged diarrhea with dehydration requiring IV fluid within 60 days prior to baseline visit
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2008
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00399438
Start Date
December 1 2006
End Date
January 1 2008
Last Update
September 26 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905